3Yu ML,Chuang WL. Treatment of chronic hepatitis C in Asia: when east meets west. J Gastroenterol Hepatol,2009,24:336-345.
4Jensen DM,Morgan TR,Marcellin P,et al. Early identification of HCV genotype 1 patients responding to 24 weeks peginter- feron alpha-2a(40 kd)/ribavinrin therapy. Hepatology,2006,43: 954-960.
5McHutchison JG,Lawitz EJ,Shiffman ML,et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med,2009,361:580-593.
6Shi XD,Pan Y,Wang M,et al. IL-28B genetic variation is associated with spontaneous clearance of hepatitis C virus, treatment response to serum IL-28 levels in Chinese popula- tion. PLoS One, 2012,7(5 ):e37054.
7Ge D,Fellay J,Thompson AJ,et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature, 2009,461:399-401.
8Tanaka Y,Nishida N,Sugiyama M,et al. Genome-wide associa- tion of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet,2009,41: 1105-1109.
9Suppiah V,Moldovan M,Ahlenstiel G,et al. IL28B is associat- ed with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet, 2009,41:1100-1104.
10Mangia A,Thompson AJ,Santoro R,et al. An IL28B polymor- phism determines treatment response of hepatitis C virus geno- type 2 or 3 patients who do not achieve a rapid virologic re- sponse. Gastroenterology,2010,139:821 - 827,827 el.
